BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/16/2022 11:52:44 AM | Browse: 670 | Download: 1627
Publication Name World Journal of Clinical Cases
Manuscript ID 76852
Country China
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Meta-Analysis
Article Title Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer
Manuscript Source Unsolicited Manuscript
All Author List Zhong-Hui Li, yinjie ma, zonghang jia, yueyan weng, ping zhang, shijie zhu and Fang Wang
ORCID
Author(s) ORCID Number
Zhong-Hui Li http://orcid.org/0000-0003-1442-6769
Fang Wang http://orcid.org/0000-0002-6054-2675
Funding Agency and Grant Number
Corresponding Author Fang Wang, MD, Chief Doctor, Department of Oncology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Wangjing Hospital, China Academy of Chinese Medical Sciences, Huajiadi Road, Beijing, Beijing 100102, China. wf074500@163.com
Key Words Metastatic pancreatic cancer; Gemcitabine; Nab-paclitaxel; Novel targeted agent; Survival
Core Tip Gemcitabine plus nab-paclitaxel (GA) is a commonly used first-line treatment regimen for metastatic pancreatic cancer, and many studies will add a novel targeted agent to this regimen to improve patient survival. However, the clinical effectiveness of GA is more controversial. We conducted a meta-analysis to compare the effectiveness and safety of GA combined with a targeted agent regimen and GA regimen.
Publish Date 2022-09-16 11:52
Citation Li ZH, Ma YJ, Jia ZH, Weng YY, Zhang P, Zhu SJ, Wang F. Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer. World J Clin Cases 2022; 10(27): 9703-9713
URL https://www.wjgnet.com/2307-8960/full/v10/i27/9703.htm
DOI https://dx.doi.org/10.12998/wjcc.v10.i27.9703
Full Article (PDF) WJCC-10-9703.pdf
Full Article (Word) WJCC-10-9703.docx